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Abstract
Background: Historically, the majority of insertable cardiac monitor (ICM) procedures were performed in the
cardiac catheterization (cath) lab, electrophysiology (EP) lab, or operating room (OR). The miniaturization of ICMs
allows the procedure to be relocated within the hospital without compromising patient safety. We sought to
estimate the rate of untoward events associated with procedures performed within the hospital but outside the
traditional settings and to characterize resource utilization, procedure time intervals, and physician experience.
Methods: The Reveal LINQ in-Office 2 (RIO 2) International study was a single arm, multicenter, prospective study.
Patients indicated for an ICM and willing to undergo device insertion outside the cath/EP lab or OR were eligible
and followed for 90 days after insertion.
Results: A total of 191 patients (45.5% female aged 63.8 ± 26.9 years) underwent successful Reveal LINQ ICM
insertion at 17 centers in Europe, Canada and Australia. The median total visit duration was 106 min (interquartile
range [IQR]: 55–61). Patient preparation and patient education accounted for 10 min (IQR: 5–20) and 10 min (IQR: 8–
15) of total visit duration, respectively. Preparation and education occurred in the procedure room for 90.6 and
60.2% of patients, respectively. There were no untoward events (0.0, 95% CI: 0.0–2.1%) though four patients
presented with procedure-related adverse events that did not require invasive intervention. Physicians rated
procedure location as convenient or very convenient.
Conclusions: The Reveal LINQ™ ICM insertion can be safely and efficiently performed in the hospital outside the
cath/EP lab or OR.
Trial registration: ClinicalTrials.gov identifier NCT02412488; registered on April 9, 2015.
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Background
Subcutaneous insertable cardiac monitors (ICMs) con-
tinuously record ECG for up to 3 years and are used
clinically for the detection of infrequent arrhythmias and
atrial fibrillation management. The traditional settings
for ICM insertion procedures have been the cardiac
catheterization (cath) lab, the electrophysiology (EP) lab
and the operating room (OR) - the same facilities used
for more complex cardiac device implants, such as pace-
makers, cardiac resynchronization therapy devices, and
implantable cardioverter defibrillators. This practice be-
came widespread due to the larger size of early ICM
models. However, miniaturization of ICM devices has re-
sulted in a less invasive insertion procedure, enabling re-
location of device insertion within the hospital to clean
rooms, procedure rooms and holding areas, and to prac-
tice offices outside the hospital walls [1]. This approach
is appealing because it could reduce costs related to the
procedure and increase physician and patient conveni-
ence and satisfaction [2, 3].
To further evaluate the safety of Reveal LINQ ICM in-
sertion within the hospital, but outside the traditional
settings, we built upon previous literature to conduct
the first prospective, international multi-site trial to as-
sess the rate of adverse events through 3months post
device insertion. The study was mainly conducted in
Europe and collected patient, physician, and detailed
staff procedure time interval data to document the re-
sources necessary for the procedure.
Methods
Study design
The Reveal LINQ™ In-Office 2 (RIO 2) International study
(NCT02412488) was a single arm, multicenter, interven-
tional post-market study. Patients at least 18 years of age
who were indicated for continuous arrhythmia monitoring
with an ICM, and who were willing to undergo ICM inser-
tion in the hospital, but outside the cath/EP lab or OR
were enrolled between September 2015 and May 2016.
Patients were followed for 90 days after ICM insertion
with scheduled in-person visits at days 30 and 90, and
unscheduled visits as needed. At each follow-up, the pa-
tient and insertion site were evaluated, and device and/
or procedure related adverse events were documented.
The primary endpoint was the occurrence of untoward
events, defined as a composite of unsuccessful ICM in-
sertion and complications related to the Reveal LINQ
ICM and/or insertion procedure. Complication was de-
fined as an adverse event (AE) resulting in death, involv-
ing termination of significant device function, or
requiring invasive intervention. Infection was catego-
rized as deep incision site or superficial. Deep incision
site infections were defined as pain, redness or drainage
at the incision site that required the device to be
removed or IV antibiotics to be administered. Superficial
infections were characterized by redness beyond proced-
ure expectation and administration of oral antibiotics.
An independent Clinical Events Committee comprised
of electrophysiologists and infection specialists who were
not study investigators determined whether each event
met the primary endpoint.
Ancillary objectives included summarizing resource
utilization, procedure duration, physician experience,
and all device and procedure related adverse events, re-
gardless of severity.
Ethics and consent to participate
All patients provided written informed consent to the
study protocol that was approved by the Human Research
Ethics Committee of each participating institution.
Insertion procedure
ICM insertion (Reveal LINQ™, model LINQ11, Medtro-
nic, Inc.) was performed in accordance with the manu-
facturer’s instructions. Device insertion took place in a
hospital location that was outside the cath/EP lab or OR
such as a procedure room, holding area or office.
Throughout the manuscript, these locations are referred
to as “out-of-lab”. Physicians were required to use the
incision and insertion tools, and to insert the device at
one of the anatomical locations listed in the Instructions
for Use. The protocol also mandated that physicians
wear sterile gloves, gown and mask during device inser-
tion, and use hand antiseptic prior to the procedure. Pa-
tients were required to be draped or wear a mask during
the procedure. Sedation was not allowed, but local
anesthesia and anxiolytic medications were permitted
and used in accordance with physician and patient pref-
erence. Use of prophylactic antibiotics was left to phys-
ician discretion and institution specific infection control
protocols. The incision was closed using adhesive strips,
surgical glue, sutures or staples.
Procedure duration and resource utilization
Procedure time intervals, procedural details, supply use,
and staffing resources were recorded during pre-
insertion preparation, and post-insertion activities. The
time intervals characterized were: (1) Visit duration:
time from patient check-in to patient discharge; (2)
Process time: time from start of patient preparation to
skin closure; (3) Procedure room time: time from when
the patient enters the procedure room to when the pa-
tient leaves the procedure room; (4) Patient preparation:
time from the start of the patient preparation to the
completion of patient preparation (including the time re-
quired for clinical assessment, changing clothes and sur-
gical site preparation); (5) Education time: time required
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to educate the patient with respect to their LINQ system
and their incision site.
Physician questionnaire
Physicians were required to complete a questionnaire
following each ICM insertion procedure that assessed
subject response, procedure delays, and physician satis-
faction. See Additional file 1 for a listing of specific
questions asked.
Sample size and statistical analysis
Based on previous studies, it was anticipated that: 1)
there would be no failed device insertion attempts, 2)
the rate of untoward events would be similar (roughly
2%) when device insertion occurred inside or outside the
cath/EP lab or OR setting, and 3) the attrition rate
would be 10%. A sample size of 204 patients was com-
puted based on the exact method to provide a target
one-sided upper 95% confidence boundary within 3% of a
point estimate based on the above assumptions. Addition-
ally, a sample size of 204 patients provided an 87% chance
to detect a rare LINQ™ insertion related complication
occurring at a true underlying rate of 1%, and a 64%
chance to detect a rare complication occurring at a true
underlying rate of 0.5%.
The exact binomial method was used to construct a
95% two-sided confidence interval for the untoward
event rate. Patients were considered evaluable for the
primary endpoint if they had an event meeting the pri-
mary endpoint, completed the 90-day in-person visit, or
had their ICM explanted during the follow-up period.
Results
Study population
The study enrolled 192 patients at 12 centers in Europe
[Germany (3), Italy (3), the Netherlands (2), Spain (1),
Sweden (1), and the United Kingdom (2)], 3 centers in
Canada, and 2 centers in Australia between September
2015 and May 2016. Enrollment was ended early (prior
to reaching the target sample size of 204) due to a lower
than expected attrition rate between the time of enroll-
ment and device insertion. Of the 192 patients enrolled,
191 underwent an ICM insertion attempt out-of-lab. All
191 insertion attempts were successful. Enrollment and
Fig. 1 Enrollment and follow-up of study participants
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follow-up of study participants is summarized in Fig. 1.
Mean follow up was 3.3 ± 0.7 months, with 98% compli-
ance to study visits.
Patient characteristics and the primary indication for
an ICM device are displayed in Table 1. Of the 191 pa-
tients with an ICM insertion, 45.5% were female. The
most common indication was syncope (53.9%), followed
by cryptogenic stroke or TIA (17.3%).
Procedural details
Most device insertions took place in a procedure room
(78%) followed by a holding area (12%, Fig. 1). Antibi-
otics were administered in 44.0% of patients prior to
ICM insertion. In all cases, antibiotics were administered
intravenously. Local anesthesia was used in 100% of in-
sertion procedures, whereas anxiolytic use only occurred
in one patient (0.5%). Most patients were draped during
device insertion (80.6%), and almost all physicians wore
a mask (99.5%), gown (89.5%), and surgical head cover-
ing (90.6%). Despite some deviations from the estab-
lished protocol during patient preparation, no apparent
increase in the risk of adverse events was established.
For 88.5% of procedures, no device repositioning was re-
quired. When repositioning was necessary (11.5% of pro-
cedures), one attempt was sufficient to achieve adequate
sensing. The device was inserted 45 degrees relative to
the sternum over the 4th intercostal space in 93.7% of
patients. Adhesive strips were the most common closure
method used (64.9% of patients) followed by sutures
(28.3%, Table 2). Post-procedure antibiotic use was
uncommon (1.6%); when used, it was administrated
intravenously.
Procedure time intervals
The total visit duration (time from check-in to dis-
charge) was 115.4 ± 73.6 min [median: 106.0, IQR: 55–
161 min]. Patient preparation accounted for 19.6 ± 25.6
min [median: 10.0 IQR: 5–20 min] and patient education
accounted for 13.1 ± 7.9 min [median: 10.0, IQR: 8–15
min] of the overall visit duration on average. The distri-
bution of procedure time intervals is displayed in Fig. 2.
Patient preparation and patient education took place in
the procedure room for 90.6 and 60.2% of patients, re-
spectively. Procedure room time was 54.1 ± 43.1 min
[median: 35.5, IQR: 24–66min].
Staffing resources
Staffing resources during pre-insertion, device insertion,
and post-insertion activities are displayed in Table 3.
The predominant staffing resources for pre-insertion ac-
tivities included registered nurses (68.1% of procedures)
and physicians (58.6% of procedures). Physicians also
participated in the majority (82.2%) of device insertions.
Cardiovascular/surgical technologists and physicians
most commonly completed post-insertion activities (52.9
and 36.1% of procedures, respectively). The mean physician
time was 10.4 ± 9.6 [median: 9.0, IQR: 5–13] minutes for
pre-insertion activities, and 12.6 ± 4.8 [median: 14.0, IQR:
10–15] minutes for post-insertion activities when physi-
cians were involved in these aspects of the procedure.
Primary objective
Of the 191 patients who received an ICM, 15 were ex-
cluded from the primary analysis due to premature exit
(10 lost to-follow-up, 5 requested withdrawal from the
study) without experiencing an untoward event. Among
the 176 patients evaluable for the primary objective
there were no untoward events. Thus, the rate of unto-
ward events was 0% with a 95% confidence interval ran-
ging from 0 to 2.1%. A missing data sensitivity analysis
indicated that patients excluded from the analysis cohort
were extremely unlikely to have had an untoward event.
ICM related adverse events
Of the 191 patients with an ICM insertion, there were
four device and/or procedure related adverse events in
four patients (Table 4); none met the primary endpoint
definition. One of the incision site hemorrhage events
was resolved when the dressing was changed; the patient
was given oral acetaminophen. At the time of the pro-
cedure, the patient was taking on antiplatelet therapy.
The other incision site hemorrhage event was resolved
by applying pressure; the patient was on oral anticoagu-
lation therapy at the time of the procedure. One patient
Table 1 Baseline patient characteristics and ICM indication




Physical Exam Findings Mean ± Standard Deviation
Age (years) 63.8 ± 26.9
Body mass index (kg/m2) 27.9 ± 4.8
Systolic blood pressure (mm Hg) 138.2 ± 21.6
Diastolic blood pressure (mm Hg) 78.6 ± 10.6
Primary Indication n (%)
Atrial fibrillation ablation monitoring 3 (1.6%)
Atrial fibrillation management 18 (9.4%)
Cryptogenic stroke or TIA 33 (17.3%)
Palpitations 7 (3.7%)
Suspected atrial fibrillation 15 (7.9%)
Syncope 103 (53.9%)
Ventricular tachycardia 2 (1.0%)
Other indication 10 (5.2%)
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experienced presyncope following incision closure due
to pain during the procedure, despite administration of
an extra dose of lidocaine. The patient’s blood pressure
was normalized within minutes by tilt/raising the pro-
cedure bed and by giving the patient several glasses of
water. Finally, no further actions were taken for the im-
plant site pain event. There were no migrations, infec-
tions or complications related to the LINQ system or
LINQ insertion procedure observed during the study.
Physician questionnaire
Responses to the physician questionnaire are displayed
in Table 5. Physicians reported that 85.9% of procedures
were not delayed over 15 min. Most physicians (90.6%)
found the procedure room facility to be convenient or
very convenient, and all physicians were satisfied or very
satisfied with the insertion environment. Physicians per-
ceived patients to respond well to device insertion, with
71.2% reporting patients having a very positive response,
and 28.8% reporting patients having a positive response.
Discussion
The RIO2 International study evaluated the safety of
performing Reveal LINQ ICM insertions in-hospital, but
outside the traditional procedure settings. It is the first
study to characterize resource utilization, procedure
time intervals, and physician satisfaction from multiple
centers across different geographies, including Europe,
Canada and Australia. All 191 insertion attempts were
successful, and no untoward events were observed
among the 176 patients evaluable for the primary end-
point during a follow-up period of 3 months. Addition-
ally, there was high compliance with the protocol
specified insertion procedure. Importantly, even under
circumstances with deviations from protocol, there was
no increase in the risk of adverse events, punctuating
the benign nature of the insertion procedure. As such,
these results provide strong evidence that the Reveal
Table 2 ICM insertion procedure details
Procedure Element Patients (N = 191)
Surgical site preparationa
None 13 (6.8%)
Shaved with razor 50 (26.2%)
Clipped 16 (8.4%)








Surgical head covering 59 (30.9%)
Insertion physician preparationa
None 0 (0.0%)
Surgical hand antiseptic in the room 69 (36.1%)
Surgical hand antiseptic outside the room 34 (17.8%)
Traditional surgical scrub in the room 48 (25.1%)
Traditional surgical scrub outside the room 72 (37.7%)




Surgical head covering 173 (90.6%)
Single layer of gloves 134 (70.2%)
Double layer of gloves 57 (29.8%)
Other 7 (3.7%)
Did patient preparation take place in the procedure room?
No 18 (9.4%)
Yes 173 (90.6%)
Location of inserted device
45-degree relative to sternum over 4th intercostal
space
179 (93.7%)
Parallel to sternum over 4th intercostal space 11 (5.8%)
Inframammary fold 0 (0.0%)
V1 ECG location 0 (0.0%)
V2 ECG location 0 (0.0%)
Other location 1 (0.5%)





No closure method used 0 (0.0%)
Table 2 ICM insertion procedure details (Continued)
Procedure Element Patients (N = 191)
Sutures 54 (28.3%)
Adhesive strips 124 (64.9%)
Surgical glue 18 (9.4%)
Staple(s) 0 (0.0%)
Location of post-procedure education
Same room as procedure 115 (60.2%)
Dedicated recovery room 59 (30.9%)
Exam room 1 (0.5%)
Waiting area 3 (1.6%)
Other location 13 (6.8%)
aCategories are not mutually exclusive and may sum to more than 100%
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LINQ ICM insertion can be safely performed out-of-lab
within the hospital by following good sterile technique
and the manufacturer’s instructions. Other studies have
assessed procedure safety outside the traditional hospital
settings. In the randomized Reveal LINQ In-Office 2
(RIO 2) study performed in the United States, low rates
of untoward events were observed when device insertion
occurred in an office outside the hospital (n = 251; 0.8%)
or in the traditional hospital setting (n = 231; 0.9%), with
no difference between groups [3]. Two observational
studies (performed in Denmark and Australia) compared
the safety of ICM insertions performed in a hospital pro-
cedure room vs. EP lab and also reported low rates of
across insertion environments (0.6–1.7%), with no sig-
nificant differences between settings [4, 5]. Absent or
low complication rates have been observed in three sin-
gle arm studies in which all device insertions occurred
in either a hospital holding area or procedure room
(0.0–0.8%) [6–8]. Importantly, the above findings dem-
onstrate similar or lower complication rates than were
observed in a combined analysis of the Reveal LINQ Us-
ability and Reveal LINQ Registry studies (0.7 and 1.6%,
respectively), where most device insertions occurred in a
cath/EP lab [9]. Finally, a recent analysis of the multi-
center Reveal LINQ Registry in a larger population (N =
1222) confirmed these observations, with 0.5% vs 1.0%
of complications occurring in patients with procedures
performed outside of the EP/cath lab vs in the EP/cath
lab, respectively [10]. Together, these findings suggest
that insertion of miniaturized ICMs can be moved out-
side the traditional hospital settings without compromis-
ing patient safety.
It is notable that no infections were observed in the
present investigation, even under circumstances requiring
Fig. 2 Distribution of procedure time intervals. Visit duration is the time from patient check-in to discharge. Process duration is the time from the start
of patient preparation to completion of the insertion procedure (skin closure). Procedure room occupancy is the time from when the patient enters
the procedure room to the time the patient leaves the procedure room. Patient preparation time is the time from the start of patient preparation to
the time patient preparation is completed. Education duration is the total time required to educate the patient on the use of their ICM device and
care of their insertion wound. The left and right box dimensions are the interquartile (IQR) range. Open circles represent individual patients
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device repositioning and despite pre-procedure antibiotics
only being administered in 44% of patients. This corre-
sponds with previous studies reporting low infection rates
across insertion environments regardless of antibiotic use.
Specifically, no infections were observed when an ICM
was inserted in either the office (n = 251) or traditional
hospital setting (n = 231) in the randomized RIO 2 US
study. In that investigation, prophylactic antibiotics were
administered to approximately 45% of patients, and the
rate did not differ between groups [3]. In addition, the Re-
veal LINQ Registry showed an infection rate of 0.7%
among patients who had the procedure performed out-of-
lab, and 0.5% for those located in-lab, with similar infec-
tion rates observed in patients irrespective of prophylactic
antibiotic administration [10]. An interim analysis of the
randomized LOOP trial did demonstrate a higher rate of
infections following device insertion in a procedure room
vs. EP lab (1.6% vs. 0.1%, p = 0.004) despite administration
of pre-procedural antibiotics in over 95% of patients [4].
However, the infection rate in the procedure room
remained low and comparable to rates observed in-lab in
other studies [9, 10]. LOOP also showed a trend for fewer
adverse events, including infections, with an increase in
physician experience. Lastly, two single arm studies where
device insertion occurred in a hospital holding area or
procedure room observed infection rates of 0.0 and 0.8%
when prophylactic antibiotics were used in none and all
insertion procedures, respectively [6, 7]. Together, these
data suggest that infection rates with miniaturized ICM
insertion are low (≤1.6%) across insertion environments ir-
respective of antibiotic prophylaxis.
One of the novelties in the present investigation was
the characterization of time intervals during the different
steps of the patient care pathway across multiple centers
and geographies (patient preparation, procedure room
occupancy, process time, education, and total visit dur-
ation). We observed that device insertion could be com-
pleted efficiently out-of-lab with an average visit
duration of 115 min, procedure room occupancy time of
54 min, and process duration of 29 min (from patient
preparation to skin closure). Others have reported on
room occupancy times and have found similar results
(55–58min) [2, 11]. Moreover, in the present study phy-
sicians reported few delays over 15 min. This corre-
sponds with findings from the RIO 2 US study, where
physicians reported fewer delays when a miniaturized
ICM was inserted in an office vs. in-lab [3]. Together,







Physician 112 (58.6%) 157 (82.2%) 69 (36.1%)
Physician assistant 48 (25.1%) 46 (24.1%) 46 (24.1%)
Nurse practitioner 22 (11.5%) 18 (9.4%) 28 (14.7%)
Registered nurse 130 (68.1%) 107 (56.0%) 43 (22.5%)
CV/OR technologista 52 (27.2%) 54 (28.3%) 101 (52.9%)
Medical assistant 11 (5.8%) 5 (2.6%) 4 (2.1%)
Other 0 (0.0%) 0 (0.0%) 1 (0.5%)
a Cardiovascular/surgical technologist
Table 4 Device and/or procedure related adverse events
Device/procedure related events Adverse Events Complications
Implant site pain 1 (1, 0.52%) 0 (0, 0%)
Incision site hemorrhage 2 (2, 1.05%) 0 (0, 0%)
Presyncope 1 (1, 0.52%) 0 (0, 0%)
TOTAL 4 (4, 2.09%) 0 (0, 0%)
Table 5 Physician questionnaire responses
Questionnaire Item Surveys
(N = 191)
How well did subject respond to LINQ insertion n (%)




Very negative 0 (0.0%)
No response 0 (0.0%)
Procedure delay > 15 min n (%)
Yes 27 (14.1%)
No 164 (85.9%)
No Response 0 (0.0%)
Estimated physician work time during “pre-service period” (minutes)
Mean ± Standard Deviation 14.9 ± 14.3
Median [Interquartile Range] 10.0 [5.0–15.0]
Estimated physician work time during “post-service period” (minutes)
Mean ± Standard Deviation 14.1 ± 10.9
Median [Interquartile Range] 15.0 [5.0–15.0]
Convenience of facility n (%)
Very convenient 136 (71.2%)
Convenient 37 (19.4%)
About the same 18 (9.4%)
Inconvenient 0 (0.0%)
Very inconvenient 0 (0.0%)
No response 0 (0.0%)
Environment satisfaction n (%)




Very dissatisfied 0 (0.0%)
No response 0 (0.0%)
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these observations suggest that moving device insertion
outside the traditional hospital settings can result in
time savings.
Another interesting finding was the involvement of
non-physician personnel throughout the care pathway.
Although physicians participated in most device inser-
tions, registered nurses and cardiovascular/surgical tech-
nologists were predominant in performing pre- and
post-insertion activities, respectively. Other single-center
studies have also described successful experiences with
non-physician providers inserting miniaturized ICMs in
ambulatory settings in terms of safety, improved patient
flow, reduced costs, and better allocation of resources [6,
11, 12].
Finally, physician perception of performing the pro-
cedure outside the traditional settings was very positive
in terms of satisfaction with the environment, conveni-
ence, and positive feedback from patients. Results from
the RIO 2 randomized study, comparing Reveal LINQ
insertions performed in-office vs in the traditional hos-
pital settings, also showed improved patient and phys-
ician experience with in-office insertions [3].
Limitations
The main limitation of the study is its nonrandomized
and single arm nature. However, safety of in-lab device in-
sertion has been well established in previous investiga-
tions. Another limitation is the fact that the sample size
was lower than estimated (191 vs. 204). In addition, the
primary endpoint could not be ascertained in 15 patients
due to early study withdrawal. However, patients were free
from adverse events at the time of study withdrawal and
the low untoward rate observed in those who were assess-
able would indicate that these patients were highly un-
likely to have experienced an untoward event. Lastly, the
study did not include a standardized approach to collect
costs, so the hospital cost burden could not be estimated.
Conclusions
Findings from the RIO 2 International study, the first
prospective, international, multicenter trial of its kind,
add to a growing body of evidence that the Reveal LINQ
ICM can be safely and efficiently inserted outside the
traditional hospital settings.
Additional file
Additional file 1: Physician Questionnaire. (PDF 89 kb)
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